Human EBAG9 activation kit by CRISPRa

CAT#: GA106109

EBAG9 CRISPRa kit - CRISPR gene activation of human estrogen receptor binding site associated antigen 9



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (2)
Goat Polyclonal Antibody against EBAG9
    • 100 ug

CNY 5,371.00


EBAG9 (Myc-DDK-tagged)-Human estrogen receptor binding site associated, antigen, 9 (EBAG9), transcript variant 1
    • 10 ug

CNY 2,400.00
CNY 3,705.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol EBAG9
Locus ID 9166
Kit Components

GA106109G1, EBAG9 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA106109G2, EBAG9 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA106109G3, EBAG9 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_001278938, NM_004215, NM_198120
Synonyms EB9; PDAF
Summary This gene was identified as an estrogen-responsive gene. Regulation of transcription by estrogen is mediated by estrogen receptor, which binds to the estrogen-responsive element found in the 5'-flanking region of this gene. The encoded protein is a tumor-associated antigen that is expressed at high frequency in a variety of cancers. Alternate splicing results in multiple transcript variants. A pseudogene of this gene has been defined on chromosome 10. [provided by RefSeq, Jul 2013]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...